Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash & Current Investments (2022 - 2025)

Historic Cash & Current Investments for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $451.6 million.

  • Day One Biopharmaceuticals' Cash & Current Investments fell 1912.72% to $451.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $451.6 million, marking a year-over-year decrease of 1912.72%. This contributed to the annual value of $531.7 million for FY2024, which is 4514.11% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Cash & Current Investments stood at $451.6 million, which was down 1912.72% from $453.1 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Cash & Current Investments high stood at $558.4 million for Q3 2024, and its period low was $262.7 million during Q1 2022.
  • In the last 4 years, Day One Biopharmaceuticals' Cash & Current Investments had a median value of $388.9 million in 2022 and averaged $403.3 million.
  • Over the last 5 years, Day One Biopharmaceuticals' Cash & Current Investments had its largest YoY gain of 4877.46% in 2025, and its largest YoY loss of 1912.72% in 2025.
  • Quarter analysis of 4 years shows Day One Biopharmaceuticals' Cash & Current Investments stood at $342.3 million in 2022, then rose by 7.03% to $366.3 million in 2023, then surged by 45.14% to $531.7 million in 2024, then decreased by 15.07% to $451.6 million in 2025.
  • Its Cash & Current Investments stands at $451.6 million for Q3 2025, versus $453.1 million for Q2 2025 and $473.0 million for Q1 2025.